Commentary: Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial

医学 安慰剂 不利影响 显著性差异 血液透析 入射(几何) 内科学 平均差 安全概况 安慰剂组 麻醉 相对风险 临床试验 统计分析 随机对照试验 外科 置信区间 统计显著性 临床终点 副作用(计算机科学)
作者
Steven N. Fishbane
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:16: 1689698-1689698 被引量:1
标识
DOI:10.3389/fphar.2025.1689698
摘要

statistical difference. In summary, the "superior efficacy" claim is may be misleading. In addition, the claim of superior safety for HSK21542 is also unsubstantiated. The safety relative to placebo was comparable: the incidence of treatment-emergent adverse events in the 0.3 μg/kg group (76.7%) was similar to placebo (73.3%). Thus, asserting an overall superior safety is incorrect. The 0.3 μg/kg HSK21542 appears to have a safety/tolerability profile similar to placebo, which is reassuring, but not "superior".High-dose (HSK21542 0.6 μg/kg) results: The findings for the higher 0.6 μg/kg dose which showed less itch relief vs placebo is under-addressed. The group difference was +1.03 points vs placebo, with a 95% CI of +0.01 to +2.07. Notably, this CI excludes zero, which implies a statistically significant worse result of the high dose vs placebo. The authors do not explicitly acknowledge this but simply describe the 0.6 μg/kg effect as "less pronounced" than that of 0.3 μg/kg and "although various efficacy endpoints in the 0.6 μg/kg dose group showed improvement from baseline, no significant dose-response relationship was observed compared to the 0.3 μg/kg dose group". These statements appear to understate the findings, as the data show a less favorable effect compared with placebo. These are understatements considering the data showed a worse effect compared to placebo. This is a relevant finding (possible U-shaped dose-response) that would be important to explore. I also note an omission in Table 2: the 5-D Itch score value is blank for the LS mean difference vs placebo for the 0.6 μg/kg group, with only the CI provided, which may be a formatting error. In summary, the significant worse lower itch improvement at 0.6 μg/kg vs placebo is an important result that warrants emphasis. In review BUSINESS USE Cross-Trial comparisons: In the discussion section, the outcomes of this Phase II trial are compared with difelikefalin trials for CKD-aP. They The authors report, that 62.1% of patients in the HSK21542 0.3 μg/kg group achieved ≥3-point WI-NRS improvement at 12 weeks, versus 49.1% and 53.4% in the Phase 3 KALM-1 and KALM-2 studies of difelikefalin, respectively. While these figures were correctly cited (2,4), cross-trial comparisons are potentially misleading. The patient population and study conditions differed and no matching or statistical comparison was performed. Contextualization is crucial important asand as directly comparing the responder percentages in separate trials without adjustment can may be misleading. The authors also draw parallels to the dose-response findings of difelikefalin's Phase II trial. They state that the lack of a dose-response (0.6 vs 0.3) in HSK21542 "mirrors the findings from the phase II study of difelikefalin, where the 0.5 μg/kg dose group exhibited better efficacy than the 1 μg/kg dose group". This comparison is may be imprecise because asthere was no statistical difference was observed between these groups, and the difelikefalin phase II trial showed a significant benefit or a trend towards a benefit of the drug vs placebo at all doses tested (0.5 μg/kg being optimal)(3). Given that the HSK21542 0.6 μg/kg dose group showed a statistically significant diminshed effect compared to placebo, drawing an analogy to difelikefalin may be misleading.Thus, considering the lack of efficacy for all HSK21542 dose groups, the analogy to difelikefalin seems misleading.Discussion: I urge recommend caution in interpreting the results of Pan et al.'s 2025 manuscript. The data do not demonstrate a significant benefit of HSK21542 0.3 μg/kg over placebo. I recommend that the authors and researchers ensure that statements in the abstract, discussion, and conclusion are fully supported by the results presented. Inadvertent mistakes, such as the missing number or minus symbol should may be corrected to avoid confusion. Comparing results to other studies without direct comparative data should be avoidedmade with caution. Accurate reporting of results with substantiated claims, will ultimately benefit the scientific community and patients by setting the stage for credible and reproducible findings in future trials. In summary, HSK21542 could be an interesting therapeutic candidate for CKD-aP, but the evidence from this Phase II study is not sufficient to prove superior efficacy and safety. We look forward to further studies that address these topics and clarify the role of HSK21542 in managing CKD-aP.In summary, authors must use care in the reporting of results. The repeated miststatements asserting efficacy in this study, when the results do not demonstrate significant efficacy vs. placebo, can be misleading for readers.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
我是老大的应助被鸢尾采纳,获得10
1秒前
周周完成签到,获得积分10
3秒前
3秒前
q额完成签到,获得积分20
4秒前
4秒前
alan发布了新的文献求助10
4秒前
小y同学发布了新的文献求助10
4秒前
maolei69完成签到,获得积分10
5秒前
123发布了新的文献求助10
6秒前
master发布了新的文献求助30
6秒前
情怀的应助被tlc_191026采纳,获得30
7秒前
7秒前
lzh关闭了lzh的文献求助
8秒前
qiuhai发布了新的文献求助10
8秒前
8秒前
星辰大海的应助被风格的好的采纳,获得10
9秒前
10秒前
任江归完成签到,获得积分10
11秒前
零负一的应助被周周周采纳,获得10
11秒前
fb1993关注了科研通微信公众号
11秒前
bluemoon发布了新的文献求助10
12秒前
12秒前
13秒前
123564的应助被corleeang采纳,获得10
13秒前
13秒前
易128_完成签到,获得积分10
15秒前
qiuhai完成签到,获得积分10
16秒前
赘婿的应助被李哈哈采纳,获得10
17秒前
高大的千秋完成签到,获得积分10
18秒前
辛夷完成签到 ,获得积分10
19秒前
SS发布了新的文献求助10
19秒前
热情的远锋的应助被corleeang采纳,获得10
20秒前
22秒前
无花果的应助被tlc_191026采纳,获得10
22秒前
25秒前
zeraphym完成签到,获得积分10
25秒前
shark发布了新的文献求助10
26秒前
无花果的应助被jjyy采纳,获得10
26秒前
刻苦松鼠完成签到,获得积分10
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183414
求助须知:如何正确求助?哪些是违规求助? 9572730
关于积分的说明 21827174
捐赠科研通 7780508
什么是DOI,文献DOI怎么找? 3434008
关于科研通互助平台的介绍 2558183
邀请新用户注册赠送积分活动 2480343